Related Experiment Video
Updated: Nov 4, 2025
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
Theranostics in Brain Tumors
Hossein Shooli1, Reza Nemati2, Hojjat Ahmadzadehfar3
1Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Moallem St, Bushehr, Iran.
Abstract:
Theranostic nuclear oncology, mainly in neuro-oncology (neurotheranostics), aims to combine cancer imaging and therapy using the same targeting molecule. This approach tries to identify patients who are most likely to benefit from tumor molecular radionuclide therapy. The ability of radioneurotheranostic agents to interact with cancer cells at the molecular level with high specificity can significantly improve the effectiveness of cancer therapy. A variety of biologic targets are under investigation for treating brain tumors. PET-based precision imaging can substantially improve the therapeutic efficacy of radiotheranostic approach in brain tumors.
Insights
Neurotheranostics combines molecular imaging and radionuclide therapy for brain tumors. This precision approach identifies patients benefiting from targeted cancer therapy, enhancing treatment effectiveness.
Area of Science:
- Nuclear oncology
- Molecular imaging
- Theranostics
Background:
- Theranostic nuclear oncology, particularly neurotheranostics, integrates molecular imaging and radionuclide therapy.
- The goal is to identify patients most likely to respond to targeted tumor molecular radionuclide therapy.
- High specificity of radioneurotheranostic agents for cancer cells can improve therapy outcomes.
Purpose of the Study:
- To explore the potential of theranostic nuclear oncology in neuro-oncology.
- To highlight the role of molecular targeting in enhancing brain tumor treatment efficacy.
- To emphasize the contribution of precision imaging in optimizing radiotheranostic approaches.
Main Methods:
- Investigating various biologic targets for brain tumor treatment.
- Utilizing molecularly targeted agents for combined imaging and therapy.
- Employing Positron Emission Tomography (PET)-based imaging for precision diagnostics.
Main Results:
- Radioneurotheranostic agents demonstrate molecular-level interaction with cancer cells.
- High specificity of these agents is crucial for effective cancer therapy.
- PET-based precision imaging significantly enhances therapeutic efficacy.
Conclusions:
- Neurotheranostics offers a promising approach for personalized brain tumor treatment.
- Targeted molecular agents and advanced imaging are key to improving therapeutic outcomes.
- Precision medicine in neuro-oncology relies on the synergy between imaging and therapy.
